NCT06511648
Clinical Trial Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT06511648 |
| Title | Erdafitinib Monotherapy or in Combination With Cetrelimab in Muscle-invasive Bladder Cancer Patients With Fibroblast Growth Factor Receptor (FGFR ) Gene Alterations (SOGUG-NEOWIN) |
| Acronym | SOGUG-NEOWIN |
| Recruitment | Recruiting |
| Gender | both |
| Phase | Phase II |
| Variant Requirements | Yes |
| Sponsors | Spanish Oncology Genito-Urinary Group |
| Indications | |
| Therapies | |
| Age Groups: | adult | senior |
| Covered Countries | ITA | GBR | FRA | ESP |
CKB BOOST